BMK1 is Involved in the Regulation of P53 Through Disrupting the PML-MDM2 Interaction

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2012 Aug 8

PMID 22869143

Citations 22

Authors

Q Yang

L Liao

X Deng

R Chen

N S Gray

J R Yates 3rd

J D Lee

Affiliations

Soon will be listed here.

Abstract

Promyelocytic leukemia protein (PML) modulates the p53 tumor suppressor through its interaction with p53 and MDM2. We found that activated big MAP kinase 1 (BMK1) preferentially associates with PML isoform IV and disrupts PML-MDM2 interaction. Doxorubicin, a common chemotherapeutic agent, is known to promote PML-mediated p53 activation in part by promoting PML-dependent MDM2 nucleolar sequestration. We discovered that BMK1 deactivation coupled with doxorubicin synergistically enhanced MDM2 nucleolar sequestration and, consequently, promoted PML-mediated p53 upregulation leading to tumor cell apoptosis in vitro and tumor regression in vivo. Collectively, these results not only suggest that BMK1 activity has a role in suppressing p53 by blocking the interaction between PML and MDM2, but also implicate that pharmacological BMK1 inhibitor should significantly enhance the anticancer capacity of doxorubicin-based chemotherapy.

Citing Articles

On the Prevalence and Roles of Proteins Undergoing Liquid-Liquid Phase Separation in the Biogenesis of PML-Bodies.

Silonov S, Mokin Y, Nedelyaev E, Smirnov E, Kuznetsova I, Turoverov K Biomolecules. 2023; 13(12).

PMID: 38136675 PMC: 10741438. DOI: 10.3390/biom13121805.

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists.

Espinosa-Gil S, Ivanova S, Alari-Pahissa E, Denizli M, Villafranca-Magdalena B, Vinas-Casas M Cell Death Dis. 2023; 14(11):715.

PMID: 37919293 PMC: 10622508. DOI: 10.1038/s41419-023-06229-6.

Regulating the p53 Tumor Suppressor Network at PML Biomolecular Condensates.

Liebl M, Hofmann T Cancers (Basel). 2022; 14(19).

PMID: 36230470 PMC: 9558958. DOI: 10.3390/cancers14194549.

The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival.

Dieguez-Martinez N, Espinosa-Gil S, Yoldi G, Megias-Roda E, Bolinaga-Ayala I, Vinas-Casas M Cell Mol Life Sci. 2022; 79(10):524.

PMID: 36123565 PMC: 9485191. DOI: 10.1007/s00018-022-04541-6.

Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis.

Giurisato E, Lonardi S, Telfer B, Lussoso S, Risa-Ebri B, Zhang J Cancer Res. 2020; 80(16):3319-3330.

PMID: 32561530 PMC: 7611207. DOI: 10.1158/0008-5472.CAN-19-2416.

References

Esparis-Ogando A, Diaz-Rodriguez E, Carlos Montero J, Yuste L, Crespo P, Pandiella A . Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol. 2001; 22(1):270-85. PMC: 134212. DOI: 10.1128/MCB.22.1.270-285.2002. View

Zhu H, Wu L, Maki C . MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem. 2003; 278(49):49286-92. DOI: 10.1074/jbc.M308302200. View

Andersen J, Lyon C, Fox A, Leung A, Lam Y, Steen H . Directed proteomic analysis of the human nucleolus. Curr Biol. 2002; 12(1):1-11. DOI: 10.1016/s0960-9822(01)00650-9. View

Polsky D, Bastian B, Hazan C, Melzer K, Pack J, Houghton A . HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 2001; 61(20):7642-6. View

Pearson G, Robinson F, Beers Gibson T, Xu B, Karandikar M, Berman K . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22(2):153-83. DOI: 10.1210/edrv.22.2.0428. View

Weldon C, Scandurro A, Rolfe K, Clayton J, Elliott S, Butler N . Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery. 2002; 132(2):293-301. DOI: 10.1067/msy.2002.125389. View

Johnson G, Lapadat R . Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298(5600):1911-2. DOI: 10.1126/science.1072682. View

Hayashi M, Kim S, Imanaka-Yoshida K, Yoshida T, Abel E, Eliceiri B . Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest. 2004; 113(8):1138-48. PMC: 385403. DOI: 10.1172/JCI19890. View

Haluska F, Hodi F . Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998; 16(2):670-82. DOI: 10.1200/JCO.1998.16.2.670. View

10.

Beech S, Lethbridge K, Killick N, McGlincy N, Leppard K . Isoforms of the promyelocytic leukemia protein differ in their effects on ND10 organization. Exp Cell Res. 2005; 307(1):109-17. DOI: 10.1016/j.yexcr.2005.03.012. View

11.

Kato Y, Kravchenko V, Tapping R, Han J, Ulevitch R, Lee J . BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 1998; 16(23):7054-66. PMC: 1170308. DOI: 10.1093/emboj/16.23.7054. View

12.

Lee J, Ulevitch R, Han J . Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun. 1995; 213(2):715-24. DOI: 10.1006/bbrc.1995.2189. View

13.

Zhou G, Bao Z, Dixon J . Components of a new human protein kinase signal transduction pathway. J Biol Chem. 1995; 270(21):12665-9. DOI: 10.1074/jbc.270.21.12665. View

14.

Abe J, Kusuhara M, Ulevitch R, Berk B, Lee J . Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem. 1996; 271(28):16586-90. DOI: 10.1074/jbc.271.28.16586. View

15.

Hayashi M, Tapping R, Chao T, Lo J, King C, Yang Y . BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem. 2001; 276(12):8631-4. DOI: 10.1074/jbc.C000838200. View

16.

Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W . The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000; 2(10):730-6. DOI: 10.1038/35036365. View

17.

Huibregtse J, Scheffner M, Howley P . A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991; 10(13):4129-35. PMC: 453163. DOI: 10.1002/j.1460-2075.1991.tb04990.x. View

18.

Bernardi R, Pandolfi P . Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007; 8(12):1006-16. DOI: 10.1038/nrm2277. View

19.

Kurki S, Latonen L, Laiho M . Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci. 2003; 116(Pt 19):3917-25. DOI: 10.1242/jcs.00714. View

20.

Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli M . Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010; 18(3):258-67. PMC: 2939729. DOI: 10.1016/j.ccr.2010.08.008. View